February 07, 2025

Novel analysis of intrinsically disordered proteins

Novel analysis of intrinsically disordered proteins

Researchers from Mainz University and EMBL Hamburg present a new approach for structurally characterising disordered proteins by combining two different analysis methods.

A new approach to characterise conformations of unstructured proteins combines two different structural methods on the specially prepared protein samples. Protein chains have labelled ends, the distance between which can be measured with fluorescence and X-ray-based techniques. The length of the dashed lines represents the radius of gyration. Credit: Daniela Velasco/EMBL

Proteins are the molecules that perform most ‘actions’ in the cell, and thus, are key for our body functions. Essentially, proteins are strings of amino acids, which, in most cases, fold like origami into a 3D structure. This enables them to do their job.

However, not all proteins are ordered. About 30% are in an intrinsically disordered, i.e. unstructured, state. This makes it difficult to establish to what extent different parts of such proteins form entanglements or extensions in a particular environment, e.g. an aqueous, cell-like solution. These aspects are fundamental to their behaviour. The more compact a protein becomes when it is isolated in an aqueous solution, the more readily it can coagulate with other proteins to form clumps.

Now, researchers from Johannes Gutenberg University Mainz (JGU) and EMBL Hamburg have come up with a new approach to characterise conformations of disordered proteins. They achieved this by combining two different structural methods to study the specially prepared protein samples.

Protein aggregation is the first stage in the formation of plaques in the brain

Intrinsically disordered proteins often result in amyloid formations. When these amyloid protein structures clump together in the brain, the deposits – also called plaques – increase the risk of developing Alzheimer’s disease and other neurodegenerative disorders. Biophysicists are thus particularly interested in the sizes of proteins in solution.

“This factor can tell us about the aggregation potential of a protein, which is the key parameter in assessing the probability of falling victim to a neurodegenerative disease. And the aggregation process is a crucial step in the formation of plaques,” explained Edward A. Lemke, Professor at the JGU Institute of Molecular Physiology and Adjunct Director of the Institute of Molecular Biology (IMB).

The problem is that there are two popular methods to measure this key parameter, and they produce inconsistent results. One technique employs fluorescence to measure the end-to-end distance, i.e. the length of a protein chain from one end to the other. Using small-angle X-ray scattering (SAXS), on the other hand, it is possible to gauge the overall size of an entangled protein or – in technical terms – its radius of gyration. “Both methods can be used for prognostic purposes, but the incompatibility of the results means that there is still uncertainty concerning this key parameter,” said Dmitri Svergun, a retired group leader of EMBL Hamburg (presently at BIOSAXS GmbH).

New approach: radius of gyration and end-to-end distance determined from a single sample

The team of researchers managed to resolve this dilemma by bringing together chemical biology and scattering methods. They combined molecular labelling and advanced scattering techniques to measure the size of protein clumps and end-to-end distance in a single sample.

Key to success were the advanced fluorescent labelling techniques at Mainz University and the high brilliance EMBL beamline P12 running at the PETRA III synchrotron in Hamburg.

“The brilliance of P12 was crucial to extract the extremely low, anomalous SAXS signal from the labelled proteins,” said Dmitri Svergun. “The use of anomalous SAXS, an advanced technique pioneered for proteins at EMBL Hamburg in the 70s, allowed us to determine the distance between the fluorescence labels together with the protein’s radius of gyration – solely from the X-ray data.”

“This way we get results for two parameters and can evaluate in what way these two are interdependent,” concluded Lemke. The researchers have been able to measure both parameters since 2017, but only in two separate samples. Now they have succeeded in determining these two parameters from a single sample, and, notably, the end-to-end distances from anomalous SAXS were compatible with the independent fluorescence results. The study provides yet more convincing insight into the architecture of unstructured proteins.


This article has been adapted from a news article by the Johannes Gutenberg University Mainz. Find the original story here.


Source article(s)

A genetically encoded anomalous SAXS ruler to probe the dimensions of intrinsically disordered proteins

Yu M.et al.
PNAS 6 December 2024
10.1073/pnas.2415220121

Decoupling of size and shape fluctuations in heteropolymeric sequences reconciles discrepancies in SAXS vs. FRET measurements

Fuertes G. et al.
PNAS 17 July 2017
10.1073/pnas.1704692114

Our latest News

discover more
European Biotech Act: bioRN brings Industry and Policymakers together

European Biotech Act: bioRN brings Industry and Policymakers together

How can Europe strengthen its global competitiveness in biotechnology? Heidelberg, July 7th: This question was at the heart of a high-level roundtable hosted by the bioRN Life Science Cluster with Member of the European Parliament Hildegard Bentele. Representatives from Ascendis Pharma, BD, PROGEN, Novaliq, BASF Agricultural Solutions, PEPperPRINT, Evotec and Isenbruck Bösl Hörschler joined the […]

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

NORTH CHICAGO, Ill., July 6, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 […]

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

It should be biofunctional – that is, it should replicate the natural cellular environment as closely as possible – and it should be printable: bioink. Achieving both of these properties at the same time is an enormous challenge that conventional biomaterials often fail to meet. Together with two partner companies, researchers at the NMI have now taken an important […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp